Skip to main content
Precision Biosensor Inc. logo

Precision Biosensor Inc. — Investor Relations & Filings

Ticker · 335810 ISIN · KR7335810008 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2026-05-15 Capital/Financing Update
Country KR South Korea
Listing KO 335810

About Precision Biosensor Inc.

https://precision-bio.com/

Precision Biosensor Inc. is an in vitro diagnostics (IVD) company that develops, manufactures, and commercializes clinical diagnostic solutions. The company specializes in point-of-care testing (POCT), providing optimized systems for on-site diagnosis. Its product portfolio includes analyzing devices and diagnostic reagents for both human and animal health. Precision Biosensor utilizes advanced technologies, such as time-resolved fluorescence (TRF), for the sensitive and accurate detection of various disease biomarkers in immuno-diagnosis and clinical chemistry applications, including cardiac markers.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 62% confidence The document is a corporate disclosure detailing the pre-maturity acquisition (repurchase) of its own convertible bonds, including amounts, dates, and methods. This is a financing activity affecting the company’s capital structure rather than a regulatory certification or a full financial report. It does not involve share vote results or director trades and is not simply a publication announcement but the substantive event itself. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is a Korean "분기보고서" (Quarterly Report) covering the 1st quarter of fiscal year 2026 (2026.01.01–2026.03.31), containing detailed company overview, capital changes, share information, articles of incorporation updates, and business analysis. It is a full interim/quarterly report with substantive financial and operational data, matching the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of convertible bonds (including overseas convertible bonds) before maturity. It includes specific financial details such as bond type, issuance date, conversion price, maturity date, acquisition amount, acquisition date, and reasons for acquisition. The document also references related disclosures about bond issuance and conversion price adjustments. This content is focused on capital structure changes and financing activities, specifically the acquisition of bonds issued by the company. The document length is 1765 characters, which is relatively short but contains substantive financial data about bond acquisition, not just an announcement of a report or a certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-05-08 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is a formal announcement of the results of the 2026 Annual General Meeting (“정기주주총회 결과”), listing each agenda item, its approval status (가결), and voting percentages. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-03-25 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 95% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Precision Bioscience (프리시젼바이오) for the fiscal year ending December 31, 2025. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. While it contains financial data, it is specifically an audit report issued by an accounting firm (Samduk Accounting Corp) rather than a company-issued 10-K or quarterly report. According to the provided definitions, standalone audit reports and results of internal/regulatory assessments fall under the 'Audit Report / Information' (AR) category. FY 2025
2026-03-17 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Precision Bioscience. It contains the auditor's opinion, financial statements (consolidated and separate), and key financial metrics for the fiscal year. While it provides financial data, it is a specific regulatory disclosure of the audit results rather than the full 10-K annual report itself. In the context of Korean regulatory filings (DART/KIND), this is classified as an Audit Report/Information document. FY 2025
2026-03-17 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.